Cargando…
Combination therapy in cancer: effects of angiogenesis inhibitors on drug pharmacokinetics and pharmacodynamics
Validated preclinical studies have provided evidence that anti-vascular endothelial growth factor (VEGF) compounds enhance the activity of subsequent antitumor therapy, but the mechanism of this potentiation is far from clear. The most widespread explanation is enhanced delivery of therapeutics due...
Autores principales: | Fuso Nerini, Ilaria, Cesca, Marta, Bizzaro, Francesca, Giavazzi, Raffaella |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4928348/ https://www.ncbi.nlm.nih.gov/pubmed/27357621 http://dx.doi.org/10.1186/s40880-016-0123-1 |
Ejemplares similares
-
Tumor Delivery of Chemotherapy Combined with Inhibitors of Angiogenesis and Vascular Targeting Agents
por: Cesca, Marta, et al.
Publicado: (2013) -
Heterogeneity of paclitaxel distribution in different tumor models assessed by MALDI mass spectrometry imaging
por: Giordano, Silvia, et al.
Publicado: (2016) -
VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
por: Bizzaro, Francesca, et al.
Publicado: (2021) -
Calcitriol in Combination Therapy for Prostate Cancer: Pharmacokinetic and Pharmacodynamic Interactions
por: Ben-Eltriki, Mohamed, et al.
Publicado: (2016) -
Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors
por: Shin, Jai Moo, et al.
Publicado: (2013)